All these findings demonstrate that BGB‐283 and compound C, unlike vemurafenib, inhibit RAF dimer in K‐RAS‐mutated cancer cells and in melanoma cells expressing the p61‐B‐RAFV600E dimer. Here, RAF1 is linked to cancer.